Sandbox Reserved 966: Difference between revisions
No edit summary |
No edit summary |
||
Line 30: | Line 30: | ||
**Helix 14 : <scene name='60/604485/H14/1'>H14</scene> | **Helix 14 : <scene name='60/604485/H14/1'>H14</scene> | ||
* There are several β sheets | * There are several <scene name='60/604485/Sheets/1'>β sheets </scene> most of them are anti parallel except <scene name='60/604485/Sheets_parrallel/1'>this one.</scene> | ||
** <scene name='60/604485/S1_ap/1'>TextToBeDisplayed</scene> | |||
** <scene name='60/604485/S2_ap/1'>TextToBeDisplayed</scene> | |||
structure classique de coude : vers 136 (à faire plus tard) | structure classique de coude : vers 136 (à faire plus tard) |
Revision as of 01:37, 10 January 2015
This Sandbox is Reserved from 15/11/2014, through 15/05/2015 for use in the course "Biomolecule" taught by Bruno Kieffer at the Strasbourg University. This reservation includes Sandbox Reserved 951 through Sandbox Reserved 975. |
To get started:
More help: Help:Editing |
Structure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor boundStructure of the "Clostridium botulinum" neurotoxin serotype A light chain with Zn2+ cofactor bound
<StructureSection load='3BON' size='340' side='right' caption='BoNT/A-LC' scene='60/604485/General_introduction/2'> The Clostridium botulinum neurotoxin produced by the bacteria Clostridium botulinum (and some strains of Clostridium butyricium and Clostridium baratii) is the most lethal toxin known today. Seven serotypically botulinum neurotoxins (BoNTs) have been found, each of them is categorized into subtypes depending on their amino acid sequence. The protein is initially synthesized as a single polypeptide chain of ≈150 kDa and is then cleaved by a protease to yield the mature toxin, which consists of a light chain (LC which is 50 kDa) and a heavy chain (HC which is 100 kDa). LC and HC are held together by a long peptide belt, non-covalent interactions and a single inter-chain disulphide bond [1] The Clostridium botulinum neurotoxin serotype A light chain (BoNT/A-LC) shown below is composed of 425 residues. It was obtained with high resolution X-ray crystal structure using an inhibitory peptide and the catalytic Zn(II) ion. [2]
StructureStructure
Global aspectGlobal aspect
The Ramachandran diagram (see Figure 1) shows the distribution of the residues in the protein. Amino acids are globally in favored regions.

The of BoNT/A-LC[3]
- The light chain of Clostridium botulinum neurotoxin serotype A has 11 α-helices :
- Helix 1 :
- Helix 2 :
- Helix 4 :
- Helix 5 :
- Helix 6 :
- Helix 7 :
- Helix 8 :
- Helix 9 :
- Helix 10 :
- Helix 11 :
- Helix 12 :
- It also has three 3-10 helices :
- Helix 3 :
- Helix 13 :
- Helix 14 :
- There are several most of them are anti parallel except
structure classique de coude : vers 136 (à faire plus tard)
Structural highlightsStructural highlights
MechanismMechanism

Therapeutic applicationsTherapeutic applications
In the late 1960s, a Edward Schantz and a San Francisco opthalmologist, Alan Scott, start to work on the using of the botulinum toxin in therapeutic process. First, they try to treat strabismus and in the late 1970s the neurotoxin is used in many therapeutic applications.[4]
Hyperhidrosis and CHARGE syndromeHyperhidrosis and CHARGE syndrome
We can now treat excessive sweating with botulinium toxin [5] thanks to its action on the receptors of the parasympathetic network. Excessive dribbling can be treated by the same way.
CosmeticCosmetic
Non-lethal amount of botulinum toxin can be injected localy to paralyse targeted muscles and reduce wrinkles temporaly[6] (5 to 6 months).
Blepharospesm, nystagmus, torticollis and strabismusBlepharospesm, nystagmus, torticollis and strabismus
This pathologic can be treated by the same methode. Every anomalous behaviour of muscle tissue can be fixed thanks to the paralyzing effect of the toxin. It is based on the muscles relaxation.
Cervical dystoniaCervical dystonia
BTX-A is used against cervical dystonia. But it can become inefficient after a periode of use.
ReferencesReferences
- ↑ Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014 Aug;12(8):535-49. doi: 10.1038/nrmicro3295. Epub 2014 Jun, 30. PMID:24975322 doi:http://dx.doi.org/10.1038/nrmicro3295
- ↑ Silvaggi NR, Wilson D, Tzipori S, Allen KN. Catalytic features of the botulinum neurotoxin a light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry. 2008 May 27;47(21):5736-45. Epub 2008 May 6. PMID:18457419 doi:10.1021/bi8001067
- ↑ http://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=3BON&bionumber=1
- ↑ http://rms.medhyg.ch/numero-200-page-870.htm
- ↑ http://rms.medhyg.ch/numero-200-page-870.htm
- ↑ http://rms.medhyg.ch/numero-200-page-870.htm